TW201613591A - Pharmaceutical compositions comprising a DEXTROMETHORPHAN compound and QUINIDINE for the treatment of agitation in dementia - Google Patents

Pharmaceutical compositions comprising a DEXTROMETHORPHAN compound and QUINIDINE for the treatment of agitation in dementia

Info

Publication number
TW201613591A
TW201613591A TW104130311A TW104130311A TW201613591A TW 201613591 A TW201613591 A TW 201613591A TW 104130311 A TW104130311 A TW 104130311A TW 104130311 A TW104130311 A TW 104130311A TW 201613591 A TW201613591 A TW 201613591A
Authority
TW
Taiwan
Prior art keywords
dementia
quinidine
agitation
treatment
pharmaceutical compositions
Prior art date
Application number
TW104130311A
Other languages
English (en)
Inventor
Joao Siffert
Original Assignee
Joao Siffert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joao Siffert filed Critical Joao Siffert
Publication of TW201613591A publication Critical patent/TW201613591A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
TW104130311A 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a DEXTROMETHORPHAN compound and QUINIDINE for the treatment of agitation in dementia TW201613591A (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201462050170P 2014-09-14 2014-09-14
US201462061451P 2014-10-08 2014-10-08
US201462063122P 2014-10-13 2014-10-13
US201462063861P 2014-10-14 2014-10-14
US201462068742P 2014-10-26 2014-10-26
US201562111053P 2015-02-02 2015-02-02
US201562111590P 2015-02-03 2015-02-03
US201562128446P 2015-03-04 2015-03-04
US201562162140P 2015-05-15 2015-05-15
US201562165535P 2015-05-22 2015-05-22
US201562169997P 2015-06-02 2015-06-02
US201562180026P 2015-06-15 2015-06-15
US201562193347P 2015-07-16 2015-07-16
US201562205061P 2015-08-14 2015-08-14
US201562216636P 2015-09-10 2015-09-10
US201562217470P 2015-09-11 2015-09-11
US201562217142P 2015-09-11 2015-09-11

Publications (1)

Publication Number Publication Date
TW201613591A true TW201613591A (en) 2016-04-16

Family

ID=55459653

Family Applications (3)

Application Number Title Priority Date Filing Date
TW104130311A TW201613591A (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a DEXTROMETHORPHAN compound and QUINIDINE for the treatment of agitation in dementia
TW109114123A TW202106301A (zh) 2014-09-14 2015-09-14 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物
TW110139834A TW202231278A (zh) 2014-09-14 2015-09-14 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW109114123A TW202106301A (zh) 2014-09-14 2015-09-14 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物
TW110139834A TW202231278A (zh) 2014-09-14 2015-09-14 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物

Country Status (14)

Country Link
US (3) US20190111047A1 (zh)
EP (4) EP3193872A4 (zh)
JP (4) JP2017531033A (zh)
KR (1) KR20170052684A (zh)
CN (3) CN117427077A (zh)
AU (3) AU2015314710A1 (zh)
CA (1) CA2960031A1 (zh)
IL (2) IL250786A0 (zh)
MX (3) MX2017003066A (zh)
PH (1) PH12017500444A1 (zh)
RU (2) RU2020116666A (zh)
SG (2) SG10201901242PA (zh)
TW (3) TW201613591A (zh)
WO (1) WO2016040930A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017020002A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
CA2994153A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CN112424600B (zh) * 2018-05-18 2023-10-10 阿纳韦克斯生命科学公司 σ-1激动剂治疗的优化和受治疗者的筛选方法
CN114712356A (zh) * 2019-01-07 2022-07-08 安泰赛普生物风投二代有限责任公司 用于治疗抑郁症的右美沙芬和安非他酮的组合
CN113825510A (zh) * 2019-03-18 2021-12-21 阿瓦尼尔制药股份有限公司 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
EP4142729A1 (en) * 2020-04-27 2023-03-08 Avanir Pharmaceuticals, Inc. Methods of treating agitation associated with alzheimer's disease
WO2022228363A1 (zh) * 2021-04-27 2022-11-03 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法
US20230131493A1 (en) * 2021-10-27 2023-04-27 Avanir Phrmaceuticals Inc. Methods of treating agitation associated with alzheimer's disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
TW264473B (zh) * 1993-01-06 1995-12-01 Hoffmann La Roche
AU8071894A (en) 1994-09-22 1996-04-09 Jonathan M Licht Compositions useful for the preparation of medicines for treating a variety of intractable disorders
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
IL136044A (en) 1997-11-21 2005-08-31 Euro Celtique Sa 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
RU2217421C2 (ru) 1998-03-26 2003-11-27 Шионоги & Ко., Лтд. Производные индола, обладающие антивирусной активностью
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
CA2641392A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
JP2009529673A (ja) * 2006-03-07 2009-08-20 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インク． 服薬遵守モニターシステム
WO2008097924A2 (en) * 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
CN102964302B (zh) 2007-05-01 2015-10-21 康塞特医药品公司 吗啡烷化合物
CN102197037B (zh) * 2008-09-19 2015-02-18 康塞特医药品公司 吗啡喃(morphinan)化合物
WO2010062692A1 (en) * 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
JP5647615B2 (ja) * 2008-11-14 2015-01-07 コンサート ファーマシューティカルズ インコーポレイテッド 置換ジオキソピペリジニルフタルイミド誘導体
EP3981404A1 (en) * 2013-11-05 2022-04-13 Antecip Bioventures II LLC Compositions and methods comprising bupropion or related compounds and dextromethorphan

Also Published As

Publication number Publication date
CN110664801A (zh) 2020-01-10
EP3193872A1 (en) 2017-07-26
US20240082237A1 (en) 2024-03-14
IL250786A0 (en) 2017-04-30
EP3932907A2 (en) 2022-01-05
EP3708168A3 (en) 2020-12-09
CN117427077A (zh) 2024-01-23
MX2021010696A (es) 2021-10-01
JP2020019818A (ja) 2020-02-06
AU2020289733A1 (en) 2021-01-21
MX2022008181A (es) 2022-08-10
TW202106301A (zh) 2021-02-16
KR20170052684A (ko) 2017-05-12
WO2016040930A1 (en) 2016-03-17
PH12017500444A1 (en) 2017-07-31
US20200289499A1 (en) 2020-09-17
US20190111047A1 (en) 2019-04-18
RU2020116666A (ru) 2020-07-31
AU2022283671A1 (en) 2023-02-02
SG10201901242PA (en) 2019-03-28
IL274742A (en) 2020-07-30
MX2017003066A (es) 2017-09-12
RU2017112747A3 (zh) 2019-04-29
TW202231278A (zh) 2022-08-16
JP2017531033A (ja) 2017-10-19
AU2015314710A1 (en) 2017-04-20
CN107072990A (zh) 2017-08-18
CA2960031A1 (en) 2016-03-17
JP2023105265A (ja) 2023-07-28
JP2021080300A (ja) 2021-05-27
EP3708168A2 (en) 2020-09-16
EP3193872A4 (en) 2018-02-28
SG11201701645WA (en) 2017-04-27
JP7360409B2 (ja) 2023-10-12
EP4166141A1 (en) 2023-04-19
RU2017112747A (ru) 2018-10-15
EP3932907A3 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2021009673A (es) Moduladores de ror-gamma.
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
IN2015DN00376A (zh)
TW201613636A (en) Methods of treating Alzheimer's Disease
EA201791993A1 (ru) Способы лечения протеинопатий
MX2019014711A (es) Polimeros de union a protones para administracion oral.
MX2021002321A (es) Nuevos metodos.
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2016008968A (es) Compuestos organicos.
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен